Intensity Modulated Radiation Therapy for Head and Neck Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00188877|
Recruitment Status : Active, not recruiting
First Posted : September 16, 2005
Last Update Posted : September 25, 2017
Many normal tissues, including the eyes, brain, and spinal cord are very close to cancers in the nasopharynx. The dose of radiation delivered to the cancer is limited by tolerance of these normal tissues. Standard radiation treatment techniques using three or four radiation beams cannot avoid delivering some dose of radiation to these normal tissues that do not need to get radiation. Intensity Modulated Radiation Therapy (IMRT) uses many hundreds of computer-controlled radiation beams aimed at your cancer to try to lower the amount of radiation that normal tissues receive, while still delivering the desired amount of radiation to your cancer and to areas that your doctor thinks may have cancer cells.
The doctors at Princess Margaret Hospital are conducting this study in order to test whether the use of IMRT techniques can improve the chance of controlling your cancer in the head and neck region.
|Condition or disease||Intervention/treatment||Phase|
|Nasopharyngeal Neoplasms||Procedure: intensity modulated radiation therapy Drug: cisplatinium and fluorouracil - standard treatment||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||44 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study of Intensity Modulated Radiation Therapy for Nasopharyngeal Cancer|
|Study Start Date :||June 2003|
|Actual Primary Completion Date :||June 2008|
|Estimated Study Completion Date :||June 2018|
- The primary objective of this study is to evaluate 3 year local progression free survival in patients with nasopharyngeal carcinoma treated with Intensity Modulated Radiation Therapy (IMRT) techniques. [ Time Frame: q2 monthly during year 1, q3 monthly during year 2; q4 monthly during year 3; q6 monthly during year 4 and annually thereafter ]
- -the ability of IMRT techniques to spare long term xerostomia as evaluated by saliva flow rates.
- -the nature and prevalence of acute and late side effects and their relationship to local dose.
- -the dosimetric differences between conventional "forward planned" two dimensional plans, three dimensional plans and Intensity modulated radiation therapy.
- -evaluation of failure with respect to the doses in the region of the failure
- -quality of life measurements in patients after receiving IMRT for the treatment of nasopharyngeal carcinoma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00188877
|Princess Margaret Hospital|
|Toronto, Ontario, Canada, M5G 2M9|
|Principal Investigator:||Andrew Bayley, MD||Princess Margaret Hospital, Canada|